

ICD-10 Procedure Coding System (ICD-10-PCS) 2022 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

XW0

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	W	Anatomical Regions	
	<i>Operation</i>	0	Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Skin	X External	2 Bromelain-enriched Proteolytic Enzyme	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	9 Satralizumab-mwge	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	H Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
FY2022	1 Subcutaneous Tissue	3 Percutaneous	V COVID-19 Vaccine Dose 3	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
FY2022	1 Subcutaneous Tissue	3 Percutaneous	W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	1 Subcutaneous Tissue	X External	2 Bromelain-enriched Proteolytic Enzyme	7 New Technology Group 7
No change	2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
FY2022	2 Muscle	3 Percutaneous	V COVID-19 Vaccine Dose 3 W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	0 Brexanolone 2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	7 Trilaciclib 8 Lurbinectedin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7

No change	3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
No change	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
No change	3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	L Lifleucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	0 Brexanolone 2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6

No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Trilaciclib 8 Lurbinectedin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6

No change	4 Central Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
No change	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic L Erdafitinib Antineoplastic	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
FY2022	D Mouth and Pharynx	X External	R Venetoclax Antineoplastic	5 New Technology Group 5
FY2022	D Mouth and Pharynx	X External	R Fostamatinib	7 New Technology Group 7
FY2022	D Mouth and Pharynx	X External	T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
FY2022	G Upper GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
FY2022	G Upper GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
FY2022	G Upper GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
FY2022	H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
FY2022	H Lower GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
FY2022	H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocagene exuparvovec	6 New Technology Group 6
No change	V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7